BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...

BNT327, a PD L1/VEGF antibody, belongs to a class of next-generation immunotherapies hoping to beat out Keytruda.

ROANOKE, Va. (WDBJ) - Friday will mark the 60th anniversary of a historic march in Selma, Alabama, where peaceful protestors ...

BNT327 combined with chemotherapy showed an overall response rate of 85.4% when used as a first-line treatment for ...

One study showed small cell lung cancer (SCLC) tumors with higher DNA damage response (DDR) activity were initially more ...

Cash and cash receivable balance of $20.9 million as of December 31, 2024, expected to fund operations, including clinical activities ...

Small-cell lung cancer (SCLC) is the most aggressive type of lung cancer. Each year in the U.S., about 30,000 to 35,000 people are diagnosed with it. For most, it has already spread to distant ...

But its most famous tenant came in 1957, when King brought the SCLC there, establishing an organizational presence in the heart of Atlanta on one of the country’s most important and recognizable ...

Combining BET inhibitors and PARP inhibitors might help patients resistant to chemotherapy, the study suggests.

Positive preliminary data from the phase 1b/2 trial evaluating Olvi-Vec in small cell lung cancer have been announced.

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) as monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not ...

Each year, the Roanoke chapter of the Southern Christian Leadership Conference (SCLC) hosts a remembrance event at the Martin Luther King, Jr. Memorial bridge and statue to remember the intent of ...